You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

Hydrogen peroxide - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for hydrogen peroxide and what is the scope of patent protection?

Hydrogen peroxide is the generic ingredient in one branded drug marketed by Aclaris and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Hydrogen peroxide has eighteen patent family members in sixteen countries.

There are four drug master file entries for hydrogen peroxide.

Summary for hydrogen peroxide
International Patents:18
US Patents:5
Tradenames:1
Applicants:1
NDAs:1
Drug Master File Entries: 4
Raw Ingredient (Bulk) Api Vendors: 155
Clinical Trials: 99
Patent Applications: 5,670
Drug Prices: Drug price trends for hydrogen peroxide
What excipients (inactive ingredients) are in hydrogen peroxide?hydrogen peroxide excipients list
DailyMed Link:hydrogen peroxide at DailyMed
Drug Prices for hydrogen peroxide

See drug prices for hydrogen peroxide

Drug Sales Revenue Trends for hydrogen peroxide

See drug sales revenues for hydrogen peroxide

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for hydrogen peroxide
Generic Entry Date for hydrogen peroxide*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION;TOPICAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for hydrogen peroxide

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Universidade Federal do ParaPhase 3
Synedgen, Inc.N/A
Louisiana State University Health Sciences Center in New OrleansN/A

See all hydrogen peroxide clinical trials

Medical Subject Heading (MeSH) Categories for hydrogen peroxide

US Patents and Regulatory Information for hydrogen peroxide

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aclaris ESKATA hydrogen peroxide SOLUTION;TOPICAL 209305-001 Dec 14, 2017 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Aclaris ESKATA hydrogen peroxide SOLUTION;TOPICAL 209305-001 Dec 14, 2017 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Aclaris ESKATA hydrogen peroxide SOLUTION;TOPICAL 209305-001 Dec 14, 2017 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Aclaris ESKATA hydrogen peroxide SOLUTION;TOPICAL 209305-001 Dec 14, 2017 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Aclaris ESKATA hydrogen peroxide SOLUTION;TOPICAL 209305-001 Dec 14, 2017 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for hydrogen peroxide

Country Patent Number Title Estimated Expiration
European Patent Office 3134061 FORMULES DE PEROXYDE ET PROCÉDÉS ET APPLICATEURS POUR LEUR UTILISATION (PEROXIDE FORMULATIONS AND METHODS AND APPLICATORS FOR USING THE SAME) ⤷  Sign Up
Denmark 3134061 ⤷  Sign Up
Poland 3134061 ⤷  Sign Up
Brazil 112016024630 composição tópica, uso de uma composição tópica e aplicador ⤷  Sign Up
Russian Federation 2016145236 ПЕРОКСИДНЫЕ КОМПОЗИЦИИ И СПОСОБЫ, И АППЛИКАТОРЫ ДЛЯ ИХ ПРИМЕНЕНИЯ ⤷  Sign Up
Japan 6622217 ⤷  Sign Up
Spain 2828711 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for hydrogen peroxide

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
3106463 122020000012 Germany ⤷  Sign Up PRODUCT NAME: LAROTRECTINIB ODER ANDERE PHARMAZEUTISCH ANNEHMBARE SALZE DAVON, EINSCHLIESSLICH LAROTRECTINIBSULFATE UMFASSEND LAROTRECTINIBHYDROGENSULFAT; REGISTRATION NO/DATE: EU/1/19/1385 20190919
3106463 CA 2020 00013 Denmark ⤷  Sign Up PRODUCT NAME: LAROTRECTINIB OG/ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, SAERLIGT LAROTRECTINIBSULFAT, INKLUSIV LAROTRECTINIBHYDROGENSULFAT; REG. NO/DATE: EU/1/19/1385 20190923
0302769 98C0036 Belgium ⤷  Sign Up PRODUCT NAME: CLOPIDOGREL HYDROGENE SULFATE; REGISTRATION NO/DATE IN FRANCE: EU/1/98 /069/001 DU 19980715; REGISTRATION NO/DATE AT EEC: DU EU/1-/98/069/001
2787345 CR 2016 00055 Denmark ⤷  Sign Up PRODUCT NAME: MIGALASTAT ELLER ET SALT HERAF, HERUNDER HYDROGENKLORIDSALTET; REG. NO/DATE: EU/1/15/1082 20160531
0281459 98C0036 France ⤷  Sign Up PRODUCT NAME: CLOPIDOGREL HYDROGENE SULFATE; REGISTRATION NO/DATE IN FRANCE: EU/1/98 /069/001 DU 19980715; REGISTRATION NO/DATE AT EEC: DU EU/1-/98/069/001
2523731 24/2020 Austria ⤷  Sign Up PRODUCT NAME: OSILODROSTAT ODER PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, EINSCHLIESSLICH OSILODROSTATDIHYDROGENPHOSPHAT; REGISTRATION NO/DATE: EU/1/19/1407 (MITTEILUNG) 20200113
3106463 2020004 Norway ⤷  Sign Up PRODUCT NAME: LAROTREKTINIB OG/ELLER FARMASOEYTISK AKSEPTABLE SALTER DERAV, SAERLIG LAROTREKTINIBSULFAT INKLUDERT LAROTREKTINIBHYDROGENSULFAT; REG. NO/DATE: EU/1/19/1385 20191018
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.